Hepatitis C

Study: 9 in 10 hepatitis C patients with cirrhosis are virus free on PEGASYS with ribavirin

Published in Hepatitis Weekly, June 17th, 2002

Early results from an ongoing study by the Swiss Association for the Study of the Liver show that PEGASYS [peginterferon alfa-2a] used in combination with a standard dose of ribavirin (1000-1200 mg) reduces hepatitis C virus (HCV) below detection levels in 93% of patients with advanced fibrosis or compensated cirrhosis after the first 24 weeks of therapy.

"These positive interim results continue to reinforce that PEGASYS combined with ribavirin is highly effective and acceptably tolerated among patients with difficult to treat disease who are in high need of therapy," said the study's principal investigator, Dr. Eberhard Renner, Head of Hepatology at the University...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2002-06-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry